Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR)

ADX:JULPHAR Balance Sheet

Financials in millions AED. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	224.5	229.6	109.1	204.8	92.3	159.3
Short-Term Investments	14	15.8	38.2	-	-	-
Trading Asset Securities	23.2	23.2	21.3	20.5	19.5	19.5
Cash & Short-Term Investments	261.7	268.6	168.6	225.3	111.8	178.8
Cash Growth	-45.92%	59.31%	-25.17%	101.52%	-37.47%	91.44%
Accounts Receivable	548.9	463.9	452.1	529	550.4	473.2
Other Receivables	42	37	368.6	31.9	34.8	110.9
Receivables	590.9	500.9	820.7	560.9	585.2	584.1
Inventory	398.3	400.9	462	661.7	672.8	653.9
Prepaid Expenses	9	9	14.1	14.8	16.2	9.5
Restricted Cash	20	20	76.2	36	-	-
Other Current Assets	289.9	285.9	474.2	82.6	76.7	73.3
Total Current Assets	1,570	1,485	2,016	1,581	1,463	1,500
Property, Plant & Equipment	252.2	254.5	314	709.1	752.3	749
Long-Term Investments	4.3	3.9	12.9	18.9	25.5	-
Other Intangible Assets	35.8	36.1	81.3	143.8	158.3	177.2
Long-Term Deferred Tax Assets	-	-	0.8	0.8	0.6	0.5
Total Assets	1,862	1,780	2,425	2,454	2,399	2,426

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	401.6	118.6	146.5	207.3	265.9	275.3
Accrued Expenses	-	154.4	136.1	105.9	114.9	154.6
Short-Term Debt	-	-	148.1	125.4	20.5	54.4
Current Portion of Long-Term Debt	15.4	-	152.5	90	37.5	-
Current Portion of Leases	3.3	3.1	15.7	38.6	39.2	31.9
Current Income Taxes Payable	19	17.2	5.2	7.7	5.9	5.9
Current Unearned Revenue	-	2.7	1.6	1.5	1.5	8.5
Other Current Liabilities	109.9	180.6	285.2	122.7	113.1	115.3
Total Current Liabilities	549.2	476.6	890.9	699.1	598.5	645.9
Long-Term Debt	248.4	263.8	612.5	765	712.5	665
Long-Term Leases	7.2	8.1	42.2	91.6	76	67.8
Pension & Post-Retirement Benefits	67	68.6	71.7	84	80.9	79.8
Long-Term Deferred Tax Liabilities	2.9	2.9	8.3	8	3.3	4
Total Liabilities	874.7	820	1,626	1,648	1,471	1,463

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	1,155	1,155	1,155	1,155	1,155	1,155
Retained Earnings	73.2	38.2	-129.9	-161.2	-65.8	-36.4
Comprehensive Income & Other	-251.9	-244.4	-236.7	-199.9	-173	-162.2
Total Common Equity	976.6	949.1	788.7	794.2	916.5	956.7
Minority Interest	10.8	10.7	10.5	12	11.7	7.1
Shareholders' Equity	987.4	959.8	799.2	806.2	928.2	963.8
Total Liabilities & Equity	1,862	1,780	2,425	2,454	2,399	2,426

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	274.3	275	971	1,111	885.7	819.1
Net Cash (Debt)	-12.6	-6.4	-802.4	-885.3	-773.9	-640.3
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-0.01	-0.01	-0.69	-0.77	-0.67	-0.55
Filing Date Shares Outstanding	1,155	1,155	1,155	1,155	1,155	1,155
Total Common Shares Outstanding	1,155	1,155	1,155	1,155	1,155	1,155
Working Capital	1,021	1,009	1,125	882.2	864.2	853.7
Book Value Per Share	0.85	0.82	0.68	0.69	0.79	0.83
Tangible Book Value	940.8	913	707.4	650.4	758.2	779.5
Tangible Book Value Per Share	0.81	0.79	0.61	0.56	0.66	0.67
Land	-	3.7	3.7	3.7	3.7	3.7
Buildings	-	370.3	368.2	508.1	508.1	505.6
Machinery	-	884.4	869.6	1,357	1,323	1,282
Construction In Progress	-	42.5	41.7	14.2	31.4	20.3
Leasehold Improvements	-	16.9	18.5	22.2	19.7	13.5

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 12, 2026

Data Sources Report a data error